Unmasking New Promises: Expanding the Antigen Landscape For Antibody–Drug Conjugates

Kumar Oberoi, Honey; Garralda Cabanas, Elena

View

Unmasking New Promises: Expanding the Antigen Landscape For Antibody–Drug Conjugates, 2021 (289.1Kb)

Author

Kumar Oberoi, Honey

Garralda Cabanas, Elena

Date

2021-08-15

Permanent link

https://hdl.handle.net/11351/7740

DOI

10.1158/1078-0432.CCR-21-1353

ISSN

1557-3265

WOS

000753846600001

PMID

34135020

Show full item record

Abstract

Cross-reactivity with normal tissues is one of the key concerns for target selection for antibody–drug conjugates. Probody therapeutics are masked antibodies that can selectively be activated by proteases in the tumor. CX-2029, is a first-in-class Probody targeting CD71 with preliminary efficacy and a tolerable safety profile

Keywords

Antibody–Drug Conjugates; Cancer treatment

Bibliographic citation

Oberoi HK, Garralda E. Unmasking new promises: expanding the antigen landscape for antibody drug conjugates. Clin Cancer Res. 2021 Aug 15;27(16):4459–61.